Director of Nursing Diane Cope Authors Study on Pain Management Considerations in Older Cancer Patients
Fort Myers, FLA., September 4, 2019 — Florida Cancer Specialists & Research Institute (FCS) Director of Nursing, Diane G. Cope, PhD, APRN, BC, AOCNP, is the author of a study that focuses on the complex considerations for managing pain in older cancer patients. Entitled “Cancer Pain Management Considerations in Older Adults,” the article was published in May 2019 in Seminars in Oncology Nursing and addresses the biological responses to drugs in older adults, as well as the movement of drugs through the body in elderly cancer patients and how these factors can impact pain management planning.
In a meta-analysis of pain management in cancer patients, only 34 of the 122 studies included in the review (about 28%) involved participants with a mean age of 65 or older. “Pain is a clinically significant and complex problem in older adults with cancer, yet little is known or understood about pain prevalence, optimal assessment and management in this unique population. Chronic pain is often perceived as an age-related condition; however, pain is not a normal part of the aging process.”
Cope points out, “Numerous factors can hinder adequate pain management in older adults with cancer,” including prevailing stereotypes and ageism that can prejudice the adequate treatment of pain in older patients. “Pain management can be hampered with fears regarding opioid side effects, such as constipation, sedation, falls and respiratory depression, resulting in undertreatment. Providers may be apprehensive about possible drug-drug interactions because of multi-morbidities and polypharmacy in older adults."
In its conclusion, the study states the management of cancer pain in older adults is a complex problem that must be based on a thorough assessment of the unique factors in each individual patient. Cope adds that oncology nurses can play a key role in this assessment and in the “education of patients and caregivers regarding pain medications, side-effects and oral adherence.”
To review an Abstract of the study: https://www.sciencedirect.com/science/article/abs/pii/S0749208119300403?via%3Dihub
About Florida Cancer Specialists & Research Institute, LLC: (FLCancer.com)
Recognized by the American Society of Clinical Oncology (ASCO) with a national Clinical Trials Participation Award, Florida Cancer Specialists & Research Institute (FCS) offers patients access to more clinical trials than any private oncology practice in Florida. In the past 4 years, the majority of new cancer drugs approved for use in the U.S. were studied in clinical trials with Florida Cancer Specialists participation.* Trained in such prestigious medical schools and research institutes as Duke, Stanford, Harvard, Emory, M.D. Anderson, and Memorial Sloan Kettering, our physicians are consistently ranked nationally as Top Doctors by U.S. News & World Report.
Founded in 1984, FCS is one of the largest medical oncology/hematology practices in the United States. With more than 230 physicians, 220 advanced practice registered nurses (APRN) and physician assistants (PA) and nearly 100 locations in our network, we are committed to providing world-class cancer care in community-based settings, close to home.
Florida Cancer Specialists has built a national reputation for excellence that is reflected in exceptional and compassionate patient care, driven by innovative clinical research, cutting-edge technologies and advanced treatments, including targeted therapies, genomic-based treatment, and immunotherapy. Our highest values are embodied by our outstanding team of highly-trained and dedicated physicians, clinicians and staff.
*Prior to approval
For More Information, Contact:
Florida Cancer Specialists & Research Institute
Shelly Glenn, Chief Marketing & Sales Officer
Michelle Robey, Director of Marketing & Communications